Benzinga | Jun 9, 2021 04:01PM EDT

Inventiva Announces 3 Scientific Presentations At EASL International Liver Congress 2021 And During A KOL Webcast Event

Daix (France), June 9, 2021 -- Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that three abstracts have been selected for presentation at the upcoming International Liver Congress(tm) 2021 hosted by the European Association for the Study of the Liver (EASL), June 23-26, 2021. Inventiva will also host a KOL webcast event on June 29, 2021, focusing on the three abstracts, the current NASH field and Inventiva's upcoming Phase III clinical trial on lanifibranor (further details below).

The first abstract focusing on the beneficial effects of lanifibranor on cardiovascular risk biomarkers has been selected for an oral presentation. Based on the results of Inventiva's NATIVE Phase IIb clinical trial evaluating lanifibranor in NASH, the authors of the abstract analyzed the change in the cardiovascular risk profile in patients with NASH by measuring several serum biomarkers. Lanifibranor showed beneficial effects on several cardiovascular risk biomarkers, including dyslipidemia, insulin resistance, inflammation and high blood pressure, confirming its promising profile as a potential treatment for NASH.

The second abstract covering the positive effects of lanifibranor on biomarkers of disease activity and associated risks in patients with NASH and F2/F3 fibrosis has also been selected for an oral presentation. Based on the results of the Company's NATIVE Phase IIb clinical trial, the authors of the abstract evaluated the effects of lanifibranor on several serum biomarkers of lipid metabolism, insulin resistance, liver injury, inflammation and fibrosis in the patient subgroup with F2/F3 fibrosis. The data showed that lanifibranor improved all selected serum biomarkers, confirming its previously reported histological efficacy, and supporting Inventiva's focus on patients with NASH and F2/F3 fibrosis in its upcoming Phase III clinical trial with lanifibranor.

The third abstract covering the beneficial effects of the combination treatment of lanifibranor and the ACC1/2 inhibitor firsocostat from Gilead in a non-clinical model of NASH and fibrosis has been accepted for a poster presentation. The results obtained in this diet-induced murine model showed the beneficial and complementary effects of the two compounds on metabolic lipids, demonstrating greater efficacy than the monotherapy for all parameters evaluated, and leading to further improvement of NASH and fibrosis. This data supports the clinical investigation of a combination of lanifibranor and firsocostat in NASH patients.

The details of the various presentations are as follows:

Abstract #1

"Lanifibranor therapy improves markers of lipid metabolism,Abstract insulin resistance, liver injury and fibrosis in patients withtitle: NASH and F2 and F3 fibrosis stages: a subgroup analysis of the Phase IIb NATIVE study"Publication 1044number:Presentation Oral presentation, abstract sessiontype: Sven Francque, Michael P. Cooreman, Martine Baudin, PhilippeAuthors: Huot-Marchand, Lucile Dzen, Jean-Louis Junien, Pierre Broqua, Manal F. AbdelmalekPresenting Prof. Sven Francque, University Hospital Antwerp, Co-Principalauthor: Investigator of the NATIVE Phase IIb clinical trialDate: June 25, 2021Session 2:15 pm - 2:30 pm CETtime:

Abstract #2

Abstract "The pan-PPAR agonist lanifibranor significantly improvestitle: cardiovascular risk biomarkers in patients with NASH "Publication 1034number:Presentation Oral presentation, abstract sessiontype: Sven Francque, Michael P. Cooreman, Martine Baudin, PhilippeAuthors: Huot-Marchand, Lucile Dzen, Jean-Louis Junien, Pierre Broqua, Manal F. AbdelmalekPresenting Prof. Sven Francque, University Hospital Antwerp, Co-Principalauthor: Investigator of the NATIVE Phase IIb clinical trialDate: June 25, 2021Session 3:00 pm - 3:15 pm CETtime:

Abstract #3

Abstract "Combination therapy of lanifibranor and firsocostat furthertitle: improves steatohepatitis and fibrosis compared to monotherapy in a Diet-Induced Murine Model of NASH"Publication 1727 number:Presentation Poster presentationtype:Authors: Guillaume Wettstein, Franc,ois Briand, Thierry Sulpice, Jean-Louis Junien and Pierre Broqua Date: June 23, 2021



KOL webcast event

To close Inventiva's participation to the EASL International Liver CongressTM 2021, the Company will host a dedicated KOL webcast event for investors and analysts at 10:00 am (ET) / 4:00 pm (CET) on June 29, 2021, covering the three abstracts mentioned above, the current NASH field, and Inventiva's upcoming Phase III clinical trial on lanifibranor.

Introduced by Fr?d?ric Cren, Chairman, CEO and cofounder of Inventiva, this event will be composed of three distinct parts, including dedicated Q&A sessions:

Part #1 :

Topic: "Review of EASL 2021 abstracts"Speaker: Prof. Sven Francque, University Hospital Antwerp, Co-Principal Investigator of the NATIVE Phase IIb clinical trial

Part #2 :

Topic: "Update on the NASH field"Speaker: Prof. Arun Sanyal, Virginia Commonwealth University, Member of Inventiva's Scientific Advisory Board

Part #3 :

Topic: "Overview of Phase III NASH trial"Speaker: Dr. Michael Cooreman, Chief Medical Officer of Inventiva



The details to connect to the webcast are the following:

Date: Tuesday, June 29, 2021Time: 10:00 am - 11:30 am (ET) / 4:00 pm - 5:30 pm (CET) Option #1 ? Webcast: https://edge.media-server.com/mmc/p/ d7qtzuzi

Option #2 ? Conference call:

France: +33 (0) 1 70 70 82 21

Belgium: +32 (0) 2 400 3439

Connection Germany: +49 (0) 69 2443 7403details: Netherlands: +31 (0) 20 715 7566

Switzerland: +41 (0) 44 580 6084

United Kingdom: +44 (0) 203 009 5709

United States: +1 646-787 1226

Access code: 6207208#

The presentation document and the link to the webcast (live and replay) will also be available on Inventiva's website in the "Investors -- Investor Presentations" section: http://inventivapharma.com/investors/investor-presentations/.